- The CDC's Advisory Committee on Immunization Practices (ACIP) has voted in favor of renewing its recommendation backing the use of AstraZeneca's (NASDAQ:AZN +0.9%) FLUMIST QUADRIVALENT (influenza vaccine live, intranasal) in the U.S. for the 2018 - 2019 season.
- ACIP made its recommendation after viewing positive results from a U.S. study in young children aged 2 to less than 4 years assessing the shedding and antibody responses of the H1N1 strain in the live attenuated flu vaccine.
CDC on board with AstraZeneca's Quadrivalent flu vaccine for next year
Recommended For You
About AZN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AZN | - | - |
AstraZeneca PLC |